Kestra Advisory Services LLC boosted its position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) by 255.7% in the third quarter, Holdings Channel.com reports. The firm owned 124,425 shares of the company’s stock after purchasing an additional 89,445 shares during the quarter. Kestra Advisory Services LLC’s holdings in SELLAS Life Sciences Group were worth $1,532,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its stake in shares of SELLAS Life Sciences Group by 293.2% during the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock valued at $27,000 after purchasing an additional 1,630 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of SELLAS Life Sciences Group by 22.4% in the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after buying an additional 1,709 shares during the period. Nykredit A S acquired a new position in shares of SELLAS Life Sciences Group in the second quarter valued at approximately $27,000. Sterling Capital Management LLC raised its holdings in SELLAS Life Sciences Group by 900.8% in the 3rd quarter. Sterling Capital Management LLC now owns 6,635 shares of the company’s stock valued at $82,000 after buying an additional 5,972 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in SELLAS Life Sciences Group by 20.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 45,691 shares of the company’s stock valued at $193,000 after buying an additional 7,673 shares during the last quarter. 17.38% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on SLS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, October 15th. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, SELLAS Life Sciences Group currently has an average rating of “Hold” and a consensus target price of $10.00.
Read Our Latest Report on SELLAS Life Sciences Group
SELLAS Life Sciences Group Stock Performance
NASDAQ:SLS opened at $17.95 on Thursday. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $1.39 and a fifty-two week high of $24.89. The company has a 50 day simple moving average of $11.09 and a two-hundred day simple moving average of $8.94. The company has a market capitalization of $3.66 billion, a PE ratio of -89.75 and a beta of 2.73.
SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05).
Latest SELLAS Life Sciences Group News
These are some of the SLS news items that stood out recently:
- Positive Sentiment: SELLAS reported that its Phase 3 REGAL trial of galinpepimut-S (GPS) met its primary endpoint in a specific group of patients with acute myeloid leukemia (AML). GPS was associated with a 41% lower risk of death and median overall survival of 24 months, versus 14.7 months with best available treatment (hazard ratio 0.59; p=0.035). The positive efficacy result is the main catalyst behind the stock’s initial surge. SELLAS REGAL trial results
- Positive Sentiment: The company said GPS was generally well tolerated, with no new safety signals, and plans to discuss an accelerated regulatory path with the FDA while preparing for a potential Biologics License Application in the first half of 2027. Trial and regulatory plans
- Neutral Sentiment: Trading activity was unusually intense, including temporary volatility-related trading pauses and a large increase in call-option volume, reflecting heightened investor interest as well as elevated volatility.
SELLAS Life Sciences Group Profile
SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.
Read More
- Five stocks we like better than SELLAS Life Sciences Group
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding SLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report).
Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.
